LUPRON VICTIMS HUB
| Home  |   Risks  | Deaths | AERS |  Documents  |  History   |  NLVN  |  Lawsuits  |  Relevant Info  |  Links  |  Media  |  Contact   

07-15-13: RxISK seeks Reports from AbbVie 'customers' (Lupron users) in campaign launched by Dr. David Healy. AbbVie, like TAP and Abbott in the past, seeks to hide clinical data - see EMA v. AbbVie .

06-14-12: Actos whistleblower reveals serious fraud, deception by Takeda

Did Abbott partner for lupron copy-cat drug "to increase revenues when patent ends on lupron [in 2015]"?

05-07-12: Settlement for Depakote claims will cost Abbott $1.6 Billion

Enantone/Lupron Victims ask for safety study by EMEA

01-26-12: Lupron sales up 8.2% at $810 million

11-07-11: 3rd Connecticut hospital this year settles allegations (paying $471,933) involving improper billing to Medicare for lupron injections.

09-10-11: Abbott Lobbying Expenditures and Abbott Campaign Finance

08-10-11: Lupron verdict in Las Vegas trial deals blow to victims

08-10-11: Billing code for female lupron has higher reimbursement rate than billing code for male lupron

08-01-11: "Trial for 'Overpriced Poison' Lupron begins in federal court" - Judge will not allow former U.S. lupron labels, foreign labels, warnings in PDR, scientific journals, or MedWatch forms to be used as evidence.

08-01-11: Follow 'Klein v. TAP/Abbott' on Twitter. See DeLuca & Nemeroff's lupron page

07-28-11: Illinois latest state to launch investigation into Dr. Mark Geier's lupron/autism 'treatment'. ... 05-04-11: Dr. Mark Geier loses license to practice medicine in Maryland because he "endangers autistic children ... by administering ... a treatment protocol [lupron] that has a known substantial risk of serious harm ...". Dr. Geier also lost his license in Washington state, a month later (and other states may follow).

07-25-11: CafePharma Message - 24 year old single mom: "I have pseudotumor cerebri - already had 2 brain surgeries to insert a shunt and will need a new surgery w/in every 10 years for the rest of my life. lupron depot is poison". (@ 10:38 am)

07-12-11: What is the cost of Lupron?

06-21-11: FDA approves 6 month formulation of lupron for prostate cancer

06-15-11: Two European countries ban Takeda's 'Actos' - FDA warns of bladder cancer risk - CafePharma flashback ... "we've been fuc**** the FDA for a year & they've only rolled over ..." (11-26-07 @ 7:58 pm)

04-27-11: "There are many clinical trials for leuprolide in Chicago ... investigating leuprolide as a new cure ..."

04-20-11: Q1 2011 Abbott results: US sales of lupron this quarter up 10% - expect approx. $750 million in global lupron sales in 2011

04-15-11: CafePharma Message - "My sister died from Abbott's crap ... Maybe we should sue the sales rep's too" (@ 5:34 pm)

02-16-11: CafePharma Message - The Lupron Scam: "so easy to sell even a cave man can do it." (@10:50 pm)

02-14-11: Anonymous Pharmaceutical Insider Speaks on 'CafePharma' Message Board (@ "3:23 pm" - at bottom of page): ... "The 6 month dosage of Lupron will KILL patients. That's being illegally marketed AGAIN for IVF, and Abbott made the Wall Street Journal 3 times in 1 week (12/10) for illegal marketing of stents and drugs. When will the corruption finally end. It's widely acknowledged that Lupron isn't a cure for anything and does more harm than good."

02-04-11: 'CafePharma' Message: "Lupron Sales Force Should Go ... under radar, over 100K for making service calls - shhhhhhhhhhhhhh"

01-29-11: 'CafePharma' Message: "... heard Lupron management took a hit. ... I'm so glad I left this shit hole company"

01-29-11: 'CafePharma' Message: "Anyone know a Lupron rep that got the Axe?"

03-20-10: 'CafePharma' Message: " ... the docs know who has buttered their bread , and we [Abbott] got very deep pockets" (@ "12:25 pm")

03-27-10: 'CafePharma' Message: "YOU DUMMY, ABBOTT PAYS MILLIONS UNDER THE TABLE SO DOCS USE LUPRON, WAKE UP YOU MORON ..." (@ "7:45 pm")

************************

June 2011: Takeda's 'Actos' gets warning: increased risk of cardiovascular complications, liver damage & bladder cancer

02-07-11: DOJ intervenes in at least 3 whistleblower lawsuits detailing Abbott's off-label marketing of Depakote. Note: Anonymous lupron sales rep alleges lupron is "being illegally marketed AGAIN for IVF (see CafePharma message on 2/14/11 @ 3:23 pm, at bottom of page). Lupron sales reps need to whistle for real.

12-23-10: $11.7 million surplus lupron settlement funds provided to Harvard prostate cancer researchers.

12-08-10: Abbott Labs agrees to pay $126.5 million in fines for defrauding gov't

12-07-10: "Deprived of the Lupron [kickback] profits, some urologists' income declined by as much as one-half" (WSJ story describes profits of a new prostate cancer treatment, and lupron is barely mentioned)

12-06-10: Senate Report: "Abbott official suggested that local connections or the 'Philly mob' should intervene to silence Baltimore Sun columnist [] for his coverage of the scandal, saying 'someone needs to take this writer outside and kick his ass!'"

December 2010: Finance Committee Staff Report on Cardiac Stent Usage at St. Joseph Medical Center

10-20-10: Long known to cause diabetes, stroke, heart attack, sudden cardiac death, Lupron gets labeling change (but for males only).

10-08-10: Abbott's weight loss drug 'Meridia' withdrawn from market due to risk of serious cardiovascular events.

Read medical expert testimony on lupron by Dr. David Redwine stating: TAP's lupron "medical fraud" is "the most egregious example of Big Pharma controlling the practice of medicine". Redwine's testimony also details how TAP attempted to entice him into prescribing lupron by an offer of $100,000.

TAP confidential memo detailing the annual $105,011.40 doctors could 'earn' when they prescribed lupron.

06-28-10: [Lupron] used for endometriosis and prostate cancer linked to misery for patients (yet another attorney ad - See 'Lawsuits' page for further attorney/lupron notices)

06-16-10: "Abbott will look to replace Lupron in the Ob/Gyn market with Elagolix" (lupron loses patent protection in 2015)

05-03-10: FDA conducting safety review of lupron in prostate cancer use

04-23-10: FDA sends Letter re: Eligard promotion

04-22-10: Lupron sales fell 10.4% to $172 million

Abbott 2009 Q4 Profits - Lupron sales down 3.6% @ $141 million

2-1-10: Two Mass. hospitals drop leuprolide depot - save $120,000 annually

11-06-09: Abbott faces new US sales probe, Depakote in Focus

10-29-09: "Even though criminal indictments were filed against TAP Pharmaceutical officials, Lupron’s price remains overly inflated."

05-21-09: Leftover $11.4 million from Lupron price inflation class action settlement may go to Harvard for prostate cancer research - update 11-16-10: Judge orders dispersement of lupron Class Settlement Funds - First Cy Press Payments to Dana Farber/Harvard Cancer Center ($400,000) [Note: the plaintiffs who were awarded the settlement funds are NOT being given the surplus funds]

Abbott CEO pay/package is rated #1 @ $33.4 million (see page 17)

Different Country's Names for leuprolide

Various New Lupron/leuprolide FDA Drug Approvals (search under 'L')

MSDS: leuprolide = "Hazardous per OSHA criteria"

Leuprolide price-gouging: 437 % mark-up

Abbott 2009 Second Quarter: Lupron Sales Increased 28.3%

||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

Millican's US Attorney Draft Document :

IIa: Was Lupron's Initial Male FDA Approval Based Upon 'Safety' and 'Efficacy'?

IIb: Was Lupron's Initial Female FDA Approval Based Upon 'Safety' and 'Efficacy'?

||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

04-26-08: Abbott makes students sick

2007: leuprolide 45 mg - FDA Notice of Initiation of Disqualification Proceedings

2005: Recall - 16,275 Lupron 7.5 & 30 mg for "clumping"

2003: Lupron diverted

06-24-02: A Whistle-Blower Rocks an Industry

Information on FDA's 1999 review of lupron, as found within Boston Herald's 8-22-99 article (beginning on pg. 2 of this link)

2001 - U.S. Dept of Justice: "TAP settles charges"

2001: TAP/Abbott sued for racketeering (Russano v. TAP/Abbott, filed 9-7-01, Federal Court, Chicago)

1-24-03: Memorandum & order on Takeda's motion to dismiss in Re: Lupron Marketing & Sales Practices Litigation (Russano & Goetting DENIED)

Substantial review of Lupron's litigation history re: racketeering can be found here (beginning on page 3)

11-18-10: Brief Review of Florida urologists' black market diversion & Medicare fraud re: lupron

2000 - Questions posed to TAP and FDA by the now-defunct NLVN about lupron

2000 - A review by the now-defunct NLVN on the FDA's role in lupron

FDA's 5-29-97 Warning Letter to TAP re: misleading claims in prostatic use

FDA's 3-9-90 letter to TAP re: misleading urology claims

FDA's '90 Notice of Adverse Findings vs. Lupron/TAP

FDA's 3-90 memo re: TAP's indocrination of MD's to lupron's off-label uses

Incomplete A-Z list of lurpon / leuprolide 'Off-Label Uses'

TAP's connection with autism patent by Kathleen Seidel

8-90 letter from TAP to Millican promoting off-label Lupron (b4 endo approval)

TAP's '90 Response to FDA

2001: Abbott/TAP designated as one of worst corporation

Lupron'$ 'Whi$tleblower'

Lupron: "Marketing The Spread" (scroll down)

1998: 53% of urologists surveyed "did not believe in efficacy" of ADT but they still prescribed it

Abbott / Takeda pay $875 million to settle Lupron Fraud Case

Review of billing fraud details

Post on CafePharma 12-22-05 (07:35 pm): "Re: Challenge: All Lupron 'Haters' Invited" - "GYNs slid under radar ..."

Medicare Reimbursement for Lupron

'98 Letter to Editor, Boston Herald, re: Lupron Fraud, Conflict$ of Interest

1992 Abbott Annual Report: Clinical studies "underway" for lupron's effectiveness in infertility (Note: Why no "safety" study, and Why hasn't lupron ever been FDA approved for infertility or IVF treatment?)

Collection of old news bits re: TAP, Abbott, lupron, etc. (i.e. Notices of Adverse Findings, FEC Warnings, Annual Report details, etc.)

Example of Using Leuprolide on Women BEFORE use of Leuprolide in Animals (note "Conclusion")

ALADDIN Study - Leuprolide & Alzheimers Trial

Example of promoting lupron for non-approved indications: "leuprolide is prescribed to shrink the fibroids"

Lupron & Fraudulent Research (Known Instances)

'96: Findings of Scientific Misconduct in TAP's lead lupron investigator

Published Lupron Article "Retracted" For Fraudulent Data (re: gyn)

Another Published Article re: Leuprolide "Retracted" Due to 'Undiscoverable Reasons' (re: autism)

 

 

 

 

 

 

 

 

 

 

This page will address some of the history of lupron, TAP (Takeda Abbott Phamaceuticals), and Abbott. After a 31 year joint venture, Takeda and Abbott dissolved their partnership in 5/08, and lupron is now under Abbott's purview.

Information related to FDA's initial approval of lupron in men and women can be found within my 'USA[ttorney] Draft Document', which contains substantive information on the following themes:

II.  WAS LUPRON'S INITIAL [MALE & FEMALE] FDA APPROVAL BASED UPON SAFETY AND EFFICACY?

III.  HAVE TAP, INVESTIGATORS, AND PHYSICIANS REPORTED ACCURATE AND FULL DATA REGARDING LUPRON?

IV.  HAVE TAP, INVESTIGATORS, AND PHYSICIANS KNOWINGLY HARMED BABIES CONCEIVED WITH LUPRON?

V.  HAVE STATE AND FEDERAL GOVERNMENT AGENCIES ACTED ON BEHALF OF CONSUMERS RELATIVE TO LUPRON?

VI.  WHAT ROLE HAS CONFLICTS OF INTEREST PLAYED IN THE HUMAN EXPERIMENTATION, SUPPRESSION OF INFORMATION, AND LACK OF MEDICO-LEGAL ADVOCACY RELATIVE TO LUPRON?

VII.  HAVE THERE ALSO BEEN GYNECOLOGICAL AND REPRODUCTIVE SCHEMES BY TAP, INVESTIGATORS AND PHSYCIANS?

-------------------

Other documents on this page pertain to TAP's propensity for off-label promotion of lupron, and TAP and Abbott's guilty pleas in Medicare and Medicaid billing fraud.

This page is under construction.

 

 


© Copyright Lynne Millican | Home | Risks | Deaths | AERSDocuments | History | NLVN | Lawsuits | Relevant InfoLinks | MediaContact